Cargando…

Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases

The problems with anticancer therapy are resistance and toxicity. From 3000 Cisplatin derivatives tested as antitumor agents, most of them have been rejected, due to toxicity. The aim of current study is the comparison of therapeutic combinations of the currently applied in clinical practice: Cispla...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsvetkova, Dobrina, Ivanova, Stefka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031877/
https://www.ncbi.nlm.nih.gov/pubmed/35458666
http://dx.doi.org/10.3390/molecules27082466
_version_ 1784692501086470144
author Tsvetkova, Dobrina
Ivanova, Stefka
author_facet Tsvetkova, Dobrina
Ivanova, Stefka
author_sort Tsvetkova, Dobrina
collection PubMed
description The problems with anticancer therapy are resistance and toxicity. From 3000 Cisplatin derivatives tested as antitumor agents, most of them have been rejected, due to toxicity. The aim of current study is the comparison of therapeutic combinations of the currently applied in clinical practice: Cisplatin, Carboplatin, Oxaliplatin, Nedaplatin, Lobaplatin, Heptaplatin, and Satraplatin. The literature data show that the strategies for the development of platinum anticancer agents and bypassing of resistance to Cisplatin derivatives and their toxicity are: combination therapy, Pt IV prodrugs, the targeted nanocarriers. The very important strategy for the improvement of the antitumor effect against different cancers is synergistic combination of Cisplatin derivatives with: (1) anticancer agents—Fluorouracil, Gemcitabine, Cytarabine, Fludarabine, Pemetrexed, Ifosfamide, Irinotecan, Topotecan, Etoposide, Amrubicin, Doxorubicin, Epirubicin, Vinorelbine, Docetaxel, Paclitaxel, Nab-Paclitaxel; (2) modulators of resistant mechanisms; (3) signaling protein inhibitors—Erlotinib; Bortezomib; Everolimus; (4) and immunotherapeutic drugs—Atezolizumab, Avelumab, Bevacizumab, Cemiplimab, Cetuximab, Durvalumab, Erlotinib, Imatinib, Necitumumab, Nimotuzumab, Nivolumab, Onartuzumab, Panitumumab, Pembrolizumab, Rilotumumab, Trastuzumab, Tremelimumab, and Sintilimab. An important approach for overcoming the drug resistance and reduction of toxicity of Cisplatin derivatives is the application of nanocarriers (polymers and liposomes), which provide improved targeted delivery, increased intracellular penetration, selective accumulation in tumor tissue, and enhanced therapeutic efficacy. The advantages of combination therapy are maximum removal of tumor cells in different phases; prevention of resistance; inhibition of the adaptation of tumor cells and their mutations; and reduction of toxicity.
format Online
Article
Text
id pubmed-9031877
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90318772022-04-23 Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases Tsvetkova, Dobrina Ivanova, Stefka Molecules Review The problems with anticancer therapy are resistance and toxicity. From 3000 Cisplatin derivatives tested as antitumor agents, most of them have been rejected, due to toxicity. The aim of current study is the comparison of therapeutic combinations of the currently applied in clinical practice: Cisplatin, Carboplatin, Oxaliplatin, Nedaplatin, Lobaplatin, Heptaplatin, and Satraplatin. The literature data show that the strategies for the development of platinum anticancer agents and bypassing of resistance to Cisplatin derivatives and their toxicity are: combination therapy, Pt IV prodrugs, the targeted nanocarriers. The very important strategy for the improvement of the antitumor effect against different cancers is synergistic combination of Cisplatin derivatives with: (1) anticancer agents—Fluorouracil, Gemcitabine, Cytarabine, Fludarabine, Pemetrexed, Ifosfamide, Irinotecan, Topotecan, Etoposide, Amrubicin, Doxorubicin, Epirubicin, Vinorelbine, Docetaxel, Paclitaxel, Nab-Paclitaxel; (2) modulators of resistant mechanisms; (3) signaling protein inhibitors—Erlotinib; Bortezomib; Everolimus; (4) and immunotherapeutic drugs—Atezolizumab, Avelumab, Bevacizumab, Cemiplimab, Cetuximab, Durvalumab, Erlotinib, Imatinib, Necitumumab, Nimotuzumab, Nivolumab, Onartuzumab, Panitumumab, Pembrolizumab, Rilotumumab, Trastuzumab, Tremelimumab, and Sintilimab. An important approach for overcoming the drug resistance and reduction of toxicity of Cisplatin derivatives is the application of nanocarriers (polymers and liposomes), which provide improved targeted delivery, increased intracellular penetration, selective accumulation in tumor tissue, and enhanced therapeutic efficacy. The advantages of combination therapy are maximum removal of tumor cells in different phases; prevention of resistance; inhibition of the adaptation of tumor cells and their mutations; and reduction of toxicity. MDPI 2022-04-11 /pmc/articles/PMC9031877/ /pubmed/35458666 http://dx.doi.org/10.3390/molecules27082466 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tsvetkova, Dobrina
Ivanova, Stefka
Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
title Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
title_full Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
title_fullStr Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
title_full_unstemmed Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
title_short Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
title_sort application of approved cisplatin derivatives in combination therapy against different cancer diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031877/
https://www.ncbi.nlm.nih.gov/pubmed/35458666
http://dx.doi.org/10.3390/molecules27082466
work_keys_str_mv AT tsvetkovadobrina applicationofapprovedcisplatinderivativesincombinationtherapyagainstdifferentcancerdiseases
AT ivanovastefka applicationofapprovedcisplatinderivativesincombinationtherapyagainstdifferentcancerdiseases